Xie Caiqin, Li Xian, Zeng Hui, Qian Wenbin
Department of Hematology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, 88# Jiefang Road, Hangzhou, 310009, Zhejiang, People's Republic of China.
Department of Hematology, First Affiliated Hospital of Jiaxing University, 1882# Zhonghuan South Road, Jiaxing, 314000, People's Republic of China.
Exp Hematol Oncol. 2020 Nov 13;9(1):30. doi: 10.1186/s40164-020-00188-w.
Peripheral T-cell lymphomas (PTCLs) are biologically and clinically heterogeneous diseases almost all of which are associated with poor outcomes. Recent advances in gene expression profiling that helps in diagnosis and prognostication of different subtypes and next-generation sequencing have given new insights into the pathogenesis and molecular pathway of PTCL. Here, we focus on a broader description of mutational insights into the common subtypes of PTCL including PTCL not other specified type, angioimmunoblastic T-cell lymphoma, anaplastic large cell lymphoma, and extra-nodal NK/T cell lymphoma, nasal type, and also present an overview of new targeted therapies currently in various stages of clinical trials.
外周T细胞淋巴瘤(PTCLs)是生物学和临床异质性疾病,几乎所有这类疾病的预后都较差。基因表达谱分析在不同亚型的诊断和预后判断方面取得的最新进展以及新一代测序技术,为PTCL的发病机制和分子途径提供了新的见解。在此,我们着重更广泛地描述对PTCL常见亚型的突变见解,包括外周T细胞淋巴瘤,非特殊类型、血管免疫母细胞性T细胞淋巴瘤、间变性大细胞淋巴瘤以及鼻型结外NK/T细胞淋巴瘤,并且还概述了目前处于临床试验不同阶段的新型靶向治疗方法。